GLP-1 C + GLP-1 S (Cagrisema)

Cagrisema is a novel combination of cagrilintide (a long-acting amylin analog) and semaglutide. This combination targets two completely distinct appetite regulatory systems simultaneously — the amylin pathway and the GLP-1 pathway — achieving additive weight loss superior to semaglutide alone.

▸The Amylin Pathway

Amylin is co-secreted with insulin from pancreatic beta cells. It:

→Slows gastric emptying (like GLP-1, but through different receptors)

→Suppresses glucagon secretion

→Acts on area postrema and hypothalamus to reduce food intake

→Produces satiety through pathways entirely separate from GLP-1

Cagrilintide is a long-acting amylin analog with a half-life suitable for once-weekly dosing — designed specifically for co-administration with semaglutide.

▸Additive Efficacy

Because amylin and GLP-1 act through completely different receptors and pathways, combining them produces additive (not redundant) appetite suppression:

Phase III REDEFINE trials: Cagrisema showed ~25% body weight reduction — compared to ~15% for semaglutide alone at comparable doses. Demonstrating clear superiority of the combination.

▸Clinical Development

Cagrisema is in Phase III trials. Early data positions it between tirzepatide and retatrutide in efficacy, with the unique advantage of an entirely different mechanism from GIP-based dual/triple agonists.